

Entrectinib and Larotrectinib: CNS Adverse Events

Entrectinib: Common CNS adverse events in the ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG trials (unresectable or metastatic solid tumors, n = 355)

CNS AEs, %	Any grade	Grade ≥3
Dysgeusia	44	0.3
Dizziness	38	0.8
Dysesthesia	34	0.3
Cognitive impairment	27	4.5
Peripheral sensory neuropathy	18	1.1
Headache	18	0.3
Ataxia	17	0.8
Sleep disturbance	14	0.6
Mood disorders	10	0.6

Additional common adverse events included fatigue, edema, constipation, diarrhea, nausea, dyspnea, myalgia, and cough

Larotrectinib: Common CNS adverse events in the LOXO-TRK-14001, SCOUT, and NAVIGATE trials (unresectable or metastatic solid tumors, n = 279)

CNS AEs, %	Any grade	Grade ≥3
Dizziness	27	1.1
Headache	15	0.4
Mood disorders	14	0.4
Cognitive impairment	11	2.5
Sleep disturbance	10	0

Additional common adverse events included fatigue, cough, constipation, diarrhea, nausea, vomiting, and pyrexia

Neuroreceptor tyrosine kinases (NTRKs) are involved the development and maintenance of the nervous system.

Entrectinib and Larotrectinib: Management of CNS Adverse Events

Dysethesias and
peripheral sensory
neuropathy